HIV negative | HIV positive | |||||
Aciclovir n (%) (N=275) | Placebo n (%) (N=309) | OR* (95% CI) | Aciclovir n (%) (N=160) | Placebo n (%) (N=155) | OR* (95% CI) | |
No of (%) visits HSV DNA detected | ||||||
Any swab | 9 (3) | 33 (11) | 0.28 (0.12 to 0.66) | 23 (14) | 30 (19) | 0.69 (0.26 to 1.85) |
pinteraction (treatment and HIV status) =0.17 | ||||||
Cervical swabs | 3 (1) | 16 (5) | 0.20 (0.05 to 0.82) | 15 (9) | 15 (10) | 0.97 (0.29 to 3.23) |
pinteraction=0.09 | ||||||
Vaginal swabs | 6 (2) | 21 (7) | 0.30 (0.10 to 0.95) | 16 (10) | 18 (12) | 0.85 (0.25 to 2.88) |
pinteraction=0.22 | ||||||
Vulval/perineal/perianal swabs | 3 (1) | 31 (10) | 0.10 (0.03 to 0.35) | 17 (11) | 26 (17) | 0.59 (0.18 to 1.92) |
pinteraction=0.05 |
↵* OR for the effect of aciclovir on HSV DNA detection compared with placebo.